Nucryst Pharmaceuticals Corp. (NCST) announced the preliminary results of the Phase II clinical trials examining the safety and efficacy of NPI 32101, a drug candidate for the treatment of atopic dermatitis.
According to the data, the success rates of both 2% and 1% NPI 32101 creams were not statistically different to that of the placebo, and therefore did not meet its efficacy endpoint.
The firm said this may be due to the higher than expected placebo response rate.
"NUCRYST is continuing to analyze data from this study so that we can evaluate options for our atopic dermatitis program with a complete understanding of the study results," said Scott H. Gillis, President & CEO, NUCRYST Pharmaceuticals.
"Based on our preclinical results in a variety of in vitro and in vivo models and the consistently favorable safety data generated in all clinical studies, we believe that NPI 32101 has the potential to treat various inflammatory and infectious conditions.
Therefore, we plan to continue our efforts to develop NPI 32101 for a variety of disease conditions."
NPI 32101 has been developed using Nucryst's patented atomically disordered nanocrystalline silver technology.
Source: Nucryst
Comment Preview